Comparing Anti-apoptotic Effects of Peroxisome Proliferator-Activated Receptor-Gamma and Angiotensin-Converting Enzyme Inhibitors using Human Umbilical Vein Endothelial Cells Exposed to Sera from Patients with Alzheimer’s Disease and Healthy Controls

Document Type : Original Article (s)

Authors

1 Faculty Member, Isfahan Neurosciences Researches Center, Isfahan University of Medical Sciences AND Assistant Professor, Department of Pharmacology, School of Medical Sciences, Islamic Azad University, Najafabad Branch, Isfahan, Iran

2 Assistant Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Instructor, Department of Biology, School of Medical Sciences, Islamic Azad University, Najafabad Branch, Isfahan, Iran

Abstract

Background: Alzheimer's disease (AD), the most frequent progressive neurodegenerative disorder, is associated with endothelial cell dysfunction. It has been presented that peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists can attenuate neurodegeneration of experimental autoimmune encephalomyelitis (EAE) and improve vascular function. On the other hand, angiotensin-converting enzyme inhibitors (ACE-I) has beneficial effects on endothelial dysfunction and endothelial surveillance. This study aimed to compare the beneficial effects of PPAR-gamma and ACE-I on human umbilical vein endothelial cells (HUVECs) treated with sera from patients with Alzheimer's disease or healthy controls.Methods: 10 patients with Alzheimer's disease and 10 healthy individuals were arranged in case and control groups, respectively. Apoptosis was identified after and before adding pioglitazone and enalapril on endothelial cells by annexin V‑propidium iodide staining and cell-death detection kit. Although, nitrite levels were diminished when the sera exposed to both drugs treated endothelial cells but this difference between them was not significant.Findings: Pioglitazone and enalapril could attenuate apoptosis rate significantly before treating with sera from patients with Alzheimer's disease but the reduction rate was more when pioglitazone added to the media. Also, nitrite concentration showed significantly greater levels of dissolved NO2/NO3 metabolite in the culture media of endothelial cells treated by sera of patients with Alzheimer's disease (P < 0.05), while the rate of nitric oxide significantly decreased when both drugs were presented in culture media.Conclusion: Overally, apoptosis rate reduced more when PPAR agonist was added than ACE-I drugs. It seems that poiglitazone stimulate more anti-apoptotic mechanisms in Alzheimer's disease.

Keywords

References

  1. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol 2011; 300(5): H1566-H1582.
  2. Casado A, Encarnacion Lopez-Fernandez M, Concepcion CM, de La TR. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 2008; 33(3): 450-8.
  3. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23(2): 168-75.
  4. Heneka MT, Landreth GE, Hull M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol 2007; 3(9): 496-504.
  5. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem 1993; 268(36): 26817-20.
  6. Ji H, Wang H, Zhang F, Li X, Xiang L, Aiguo S. PPARgamma agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Inflamm Res 2010; 59(11): 921-9.
  7. Werner C, Kamani CH, Gensch C, Bohm M, Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007; 56(10): 2609-15.
  8. Raikwar HP, Muthian G, Rajasingh J, Johnson CN, Bright JJ. PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2. J Neuroimmunol 2006; 178(1-2): 76-86.
  9. Gray E, Ginty M, Kemp K, Scolding N, Wilkins A. The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflammation 2012; 9: 63.
  10. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 2007; 1771(8): 952-60.
  11. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'Amico MA, D'Angelo B, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005; 130(2): 325-37.
  12. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009; 169(13): 1195-202.
  13. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63(7): 1324-5.
  14. Benzie IF, Tomlinson B. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro. Br J Clin Pharmacol 1998; 45(2): 168-9.
  15. Law A, Gauthier S, Quirion R. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res Brain Res Rev 2001; 35(1): 73-96.
  16. Hornig B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19)Suppl G(: G48-G53.
  17. Cesari M, Kritchevsky SB, Atkinson HH, Penninx BW, Di BM, Tracy RP, et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J 2009; 157(2): 334-8.
  18. Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH. Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis 2001; 8(6): 1006-16.
  19. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006; 9(2): 167-81.
  20. Vural H, Sirin B, Yilmaz N, Eren I, Delibas N. The role of arginine-nitric oxide pathway in patients with Alzheimer disease. Biol Trace Elem Res 2009; 129(1-3): 58-64.
  21. Hagiwara S, Iwasaka H, Matumoto S, Hidaka S, Noguchi T. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit Care Med 2009; 37(2): 626-33.
  22. Calissano P, Matrone C, Amadoro G. Apoptosis and in vitro Alzheimer disease neuronal models. Commun Integr Biol 2009; 2(2): 163-9.
  23. De GC, V, Rossoni G, Rigamonti A, Bonomo S, Manfredi B, Berti F, et al. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol 2002; 450(1): 61-6.
  24. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J 2011; 25(9): 2911-20.
  25. Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007; 21(6): 423-9.
Journal of Isfahan Medical School
Volume 31, Issue 264 - Serial Number 264
November and December 2014
Pages 1997-2004

Files

History

  • Receive Date: 03 July 2013
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics